OncLive® On Air

S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

12 Sep 2022

Contributed by Lukas

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent...

S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

08 Sep 2022

Contributed by Lukas

Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH tri...

S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer

05 Sep 2022

Contributed by Lukas

Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety dat...

S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers

01 Sep 2022

Contributed by Lukas

Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient pro...

S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors

29 Aug 2022

Contributed by Lukas

Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2...

S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC

25 Aug 2022

Contributed by Lukas

Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the D...

S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer

22 Aug 2022

Contributed by Lukas

Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing ...

S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates

18 Aug 2022

Contributed by Lukas

Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these d...

S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

15 Aug 2022

Contributed by Lukas

Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the signifi...

S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer

11 Aug 2022

Contributed by Lukas

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiat...

S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field

08 Aug 2022

Contributed by Lukas

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to...

S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes

04 Aug 2022

Contributed by Lukas

Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment ...

S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

01 Aug 2022

Contributed by Lukas

Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a...

S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

28 Jul 2022

Contributed by Lukas

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM ...

S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma

25 Jul 2022

Contributed by Lukas

Dr Wagner talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward,...

S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors

21 Jul 2022

Contributed by Lukas

Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with B...

S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

18 Jul 2022

Contributed by Lukas

Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in pa...

S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine

14 Jul 2022

Contributed by Lukas

Dr Jain discusses an article she authored, titled “We’re Running Up the Wrong Side of the Escalator,” which confronts systemic and structural ob...

S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer

11 Jul 2022

Contributed by Lukas

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interf...

S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer

07 Jul 2022

Contributed by Lukas

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer ...

S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)

04 Jul 2022

Contributed by Lukas

Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particu...

S7 Ep10: Duma Discusses the Unique Challenges of Women With Lung Cancer

30 Jun 2022

Contributed by Lukas

Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gend...

S7 Ep9: Leukemia Pioneers Chronicle Career Experiences and Milestones

27 Jun 2022

Contributed by Lukas

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the...

S7 Ep8: Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer

23 Jun 2022

Contributed by Lukas

Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the ga...

S7 Ep7: Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer

20 Jun 2022

Contributed by Lukas

Dr Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treat...

S7 Ep6: Lee Lays Out Treatment Developments in Non–Clear Cell RCC

16 Jun 2022

Contributed by Lukas

Dr Lee highlights the latest treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for more precise classification of t...

S7 Ep5: Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC

13 Jun 2022

Contributed by Lukas

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the c...

S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs

09 Jun 2022

Contributed by Lukas

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evalua...

S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

06 Jun 2022

Contributed by Lukas

Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of old...

S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

02 Jun 2022

Contributed by Lukas

Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent a...

S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology

30 May 2022

Contributed by Lukas

Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challe...

S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer

26 May 2022

Contributed by Lukas

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historica...

S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

23 May 2022

Contributed by Lukas

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the gen...

S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma

19 May 2022

Contributed by Lukas

Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and wa...

S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC

16 May 2022

Contributed by Lukas

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and finding...

S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer

12 May 2022

Contributed by Lukas

Dr Pegram discusses treatment sequencing in metastatic HER2-positive breast cancer, recent updates to the National Comprehensive Cancer Network guidel...

S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC

09 May 2022

Contributed by Lukas

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situat...

S6 Ep44: Borgen Recommends Revamping Peer Review for a Post-COVID-19 World

05 May 2022

Contributed by Lukas

Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendation...

S6 Ep43: FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

02 May 2022

Contributed by Lukas

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effe...

S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML

28 Apr 2022

Contributed by Lukas

Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL ...

S6 Ep41: Bardia Reflects on Important Data in HER2+ Breast Cancer

21 Apr 2022

Contributed by Lukas

Dr Bardia discusses data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented ...

S6 Ep40: D'Abreo Addresses AEs in Metastatic Breast Cancer Care

14 Apr 2022

Contributed by Lukas

Dr D’Abreo discusses adverse effects such as fatigue, nausea and vomiting, and interstitial lung disease, shares advice on establishing an open chan...

S6 Ep39: Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis

07 Apr 2022

Contributed by Lukas

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with bre...

S6 Ep38: FDA Approval Insights: Pacritinib in Myelofibrosis

31 Mar 2022

Contributed by Lukas

Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, an...

S6 Ep37: Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022

24 Mar 2022

Contributed by Lukas

Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an in...

S6 Ep36: Lyle and Patel Examine Diagnostic and Management Paradigms in MDS

17 Mar 2022

Contributed by Lukas

Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment land...

S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC

10 Mar 2022

Contributed by Lukas

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patie...

S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

03 Mar 2022

Contributed by Lukas

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regard...

S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer

24 Feb 2022

Contributed by Lukas

Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and managem...

S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1

17 Feb 2022

Contributed by Lukas

Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tu...

S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies

10 Feb 2022

Contributed by Lukas

We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in par...

S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer

07 Feb 2022

Contributed by Lukas

Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of t...

S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma

03 Feb 2022

Contributed by Lukas

Dr Furman discussed the rarity of pediatric neuroblastoma, treatment options and expected outcomes for patients, and ongoing clinical trials in this s...

S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia

31 Jan 2022

Contributed by Lukas

Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the ...

S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine

27 Jan 2022

Contributed by Lukas

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and thei...

S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

20 Jan 2022

Contributed by Lukas

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that...

S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL

17 Jan 2022

Contributed by Lukas

Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with cov...

S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology

13 Jan 2022

Contributed by Lukas

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that...

S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma

10 Jan 2022

Contributed by Lukas

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient popu...

S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer

06 Jan 2022

Contributed by Lukas

Dr Dietz discusses her experience as a woman in surgical oncology, the importance of bridging gender disparities, and her advice to women entering the...

S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt

03 Jan 2022

Contributed by Lukas

Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center ...

S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC

30 Dec 2021

Contributed by Lukas

Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the...

S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma

27 Dec 2021

Contributed by Lukas

Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential ...

S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL

23 Dec 2021

Contributed by Lukas

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with i...

S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

20 Dec 2021

Contributed by Lukas

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in AR-positive, ER-positive advanced breast cancer, phase 2 data with the agent, and ex...

S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers

16 Dec 2021

Contributed by Lukas

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combi...

S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies

13 Dec 2021

Contributed by Lukas

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and commu...

S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL

09 Dec 2021

Contributed by Lukas

Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including...

S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC

06 Dec 2021

Contributed by Lukas

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal...

S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology

02 Dec 2021

Contributed by Lukas

Dr. Bleicher and Dr. Nardello discuss the process of finding a mentor, what to look for in a fellowship program, and the benefits of fellowship for bo...

S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma

29 Nov 2021

Contributed by Lukas

Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achie...

S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer

25 Nov 2021

Contributed by Lukas

Bryson Katona, MD, of Penn Medicine, discusses the hallmarks of hereditary diffuse gastric cancer.

S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

22 Nov 2021

Contributed by Lukas

Dr. Allison highlights everything from his proudest professional moments, to MD Anderson’s Moon Shot program, to his musical talents, to next steps ...

S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

18 Nov 2021

Contributed by Lukas

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treat...

S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer

15 Nov 2021

Contributed by Lukas

Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the...

S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer

11 Nov 2021

Contributed by Lukas

Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing res...

S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer

08 Nov 2021

Contributed by Lukas

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line se...

S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma

04 Nov 2021

Contributed by Lukas

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to ...

S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

01 Nov 2021

Contributed by Lukas

Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the piv...

S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases

28 Oct 2021

Contributed by Lukas

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factor...

S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC

25 Oct 2021

Contributed by Lukas

In our exclusive interview, Johnson discussed the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoin...

S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

21 Oct 2021

Contributed by Lukas

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 v...

S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers

18 Oct 2021

Contributed by Lukas

Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the fro...

S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing

14 Oct 2021

Contributed by Lukas

Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of t...

S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology

11 Oct 2021

Contributed by Lukas

Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatmen...

S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

07 Oct 2021

Contributed by Lukas

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been ...

S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

04 Oct 2021

Contributed by Lukas

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positi...

S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?

30 Sep 2021

Contributed by Lukas

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation t...

S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC

27 Sep 2021

Contributed by Lukas

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the stud...

S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

23 Sep 2021

Contributed by Lukas

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cerv...

S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

20 Sep 2021

Contributed by Lukas

Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.

S5 Ep42: Neel on Maximizing Research Strides in Oncology

16 Sep 2021

Contributed by Lukas

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and ...

S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer

13 Sep 2021

Contributed by Lukas

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicitie...

S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer

09 Sep 2021

Contributed by Lukas

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of th...

S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC

06 Sep 2021

Contributed by Lukas

Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuance...

S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

02 Sep 2021

Contributed by Lukas

Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, a...

S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

30 Aug 2021

Contributed by Lukas

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential u...

S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer

26 Aug 2021

Contributed by Lukas

Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, an...

S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer

23 Aug 2021

Contributed by Lukas

Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for...

S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19

19 Aug 2021

Contributed by Lukas

Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests and its link with potential racial disparities from the COVI...